

A Unit of Vijaya Diagnostic Centre - Hyderabad

CIN no: L85110TG1993PLC015481

May17, 2022

To
The Corporate Relations Department
BSE Limited,
Phiroze Jeejeebhoy Towers,
25<sup>th</sup> Floor, Dalal Street,
Mumbai - 400001
Company Code No. 526301

Dear Sir/Madam

Subject: Outcome of the Board Meeting held on May17, 2022.

We hereby inform you that, the Board of Directors in their meeting held today i.e. on Tuesday May 17, 2022 has inter-alia considered and approved:

1. The Audited Standalone and Consolidated Financial Results of the Company for the financial year ended March 31, 2022.

The aforesaid financial results together with the Audit reports issued by M/s. M. Anandam & Co., Chartered Accountants, Statutory Auditors of the Company are enclosed herewith as Annexure A.

Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby confirm and declare that our Statutory Auditors M/s. M. Anandam & Co., issued the Auditor's Report with "unmodified opinion" on the Audited Standalone and Consolidated Financial Results for the financialyear ended March 31, 2022.

2. Appointment of Ms. Anusha Kanumuru, as Company Secretary & Compliance Officer of the Company. The brief details of the appointee are enclosed herewith as Annexure B.

The Meeting commenced at 12.00 p.m. and concluded at 2.45 p.m.

Kindly take the same on record.

Thanking You

For Medinova Diagnostic Services Limited

Sunil Chandra Kondapally

Managing Director

DIN: 01409332

Encl.: As above





enabling diagnosis. ensuring health A Unit of Vijaya Diagnostic Centre – Hyderabad CIN no: L85110TG1993PLC015481

### Annexure B

# Details pertaining to appointment:

Name of the Appointee	Ms. Anusha Kanumuru
Reason for Appointment	Appointment as the Company Secretary and Compliance Officer of the Company pursuant to Regulation 6(1) of the Securities & Exchange Board of India(Listing Obligations and Disclosure Requirements)Regulations, 2015 and Section 203 of the Companies Act, 2013.
Date of appointment & term of appointment	May 17, 2022. On such terms as mutually agreed between the Company and the appointee.
Brief Profile	Ms.Anusha Kanumuru is an Associate member of the Institute of Company Secretaries of India. She has 12 plus years of experience in the Secretarial, FEMA and legal Compliances.



# MEDINOVA DIAGNOSTIC SERVICES LIMITED CIN: L85110TG1993PLC015481

Regd. Office: 7-1-58/A/FF8, Flat No. 8, Amrutha Business Complex, Ameerpet, Hyderabad - 500 016.

STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2022

(Rs. in Lakhs)

			Quarter Ended		Year I	Ended
SI. No.	Particulars	31.03.2022 (Audited)	31.12.2021 (Unaudited)	31.03.2021 (Audited)	31.03.2022 (Audited)	31.03.2021 (Audited)
1	Income:					
	(a) Revenue from Operations	224.99	217.22	227.11	1,151.38	1,131.63
	(b) Other Income	5.12	7.13	9.67	21.74	29.39
	Total Income	230.11	224.35	236.78	1,173.12	1,161.02
2	Expenses	5 45				
	(a) Cost of Materials Consumed	37.74	54.79	43.43	243.52	146.65
	(b) Employee Benefits Expense	44.70	46.17	38.89	181.99	158.57
	(c) Testing Fees	24.86	14.44	24.29	174.80	334.68
	(d) Finance Costs	12.07	10.48	7.41	41.03	30.87
	(e) Depreciation and amortisation expenses	6.83	6.53	8.50	26.01	32.19
	(f) Other Expenses	67.99	56.66	60.62	250.38	228.81
	Total Expenses	194.19	189.07	183.14	917.73	931.77
3	Profit before Tax [1-2]	35.92	35.28	53.64	255.39	229.25
4	Tax Expense					
	(a) Current Tax	5.84	9.27	7.07	60.46	8.51
	(b) Earlier Year's Tax	10.09	1.14	-	11.23	0.43
	(c) Deferred Tax	(5.91)	(5.97)	3.74	(23.70)	3.74
	Total tax expense	10.02	4.44	10.81	47.99	12.68
5	Profit for the period (3-4)	25.90	30.84	42.83	207.40	216.57
6	Other Comprehensive Income				1	
	Items that will not be reclassified to Profit or Loss (Net of tax)					
	Remeasurement of defined benefit plans	2.75	(0.22)	(4.82)	2.09	(4.82)
	Income tax relating to above	(0.53)	`- '	- 1	(0.53)	'-
7	Total Comprehensive Income for the period (5+6)	28.12	30.62	38.01	208.96	211.75
8	Paid-up Equity Share capital					
	(Face Value Rs 10/- per share)	995.68	995.68	995.68	995.68	995.68
9	Earnings per Equity Share (not annualised)	1				
	a) Basic (Rs.)	0.26	0.31	0.43	2.08	2.17
	b) Diluted (Rs.)	0.26	0.31	0.43	2.08	2.17

### Notes

- 1. The above standalone financial results of Medinova Diagnostic Services Limited ("the company") have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 2. The above standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 17th May, 2022. The Statutory Auditors of the Company have expressed an unmodified audit opinion on these results.
- 3.During the quarter ended 31st March 2022, the Company has acquired balance partnership stake (approx 44.93%) in Medinova Millennium MRI Services LLP.
- 4.The figures for the quarters ended 31 March 2022 and 31 March 2021 are the balancing figures between audited figures in respect of full financial years and the published unaudited year to date figures up to third quarter of the respective financial years.
- 5. The Company has one reportable segment (viz. Diagnostic Services) as per the requirements of Ind AS 108 "Operating Segments".
- 6. The Company has considered internal and external sources of information up to the date of approval of these financial results in evaluating the possible affects that may result from the pandemic relating to COVID-19 on the carrying amounts of the assets. The Company has applied prudence in arriving at the estimates and assumptions.

7. Previous period figures have been regrouped/reclassified, as considered necessary, to conform with the current period presentation, wherever applicable

For MEDINOVA DIAGNOSTIC SERVICES LTD

Place: Hyderabad Date: 17.05.2022 SUNII CHANDRA KONDAPALLY MANAGING DIRECTOR DIN 01409332

For Identification

4

# MEDINOVA DIAGNOSTIC SERVICES LIMITED

#### CIN: L85110TG1993PLC015481

Regd. Office: 7-1-58/A/ FF8, Flat No. 8, Amrutha Business Complex, Ameerpet, Hyderabad - 500 016.

STANDALONE BALANCE SHEET AS ON 31ST MARCH, 2022

CI	T		(Rs. in Lakhs)
SI No.	Particulars	As at 31.03.2022 (Audited	31.03.2021
14/11/2	ASSETS	(**************************************	(raunted)
I	Non-current assets		
	(a) Property, plant and equipment	79.18	89.67
	(b) Intangible assets	0.65	-
	(c) Financial assets		
	(i) Investments	296.82	126.82
	(ii) Other financial assets	13.85	
	(d) Deferred tax assets (net)	60.59	
	(e) Non-current tax assets (net)	13.52	(5),0,0,0
	Total non-current assets	464.61	298.88
II	Current assets		
	(a) Inventories	16.56	12.00
	(b) Financial assets	10.50	13.06
	(i) Trade receivables	50.29	77.16
	(ii) Cash and cash equivalents	50.28	77.16
	(iii) Bank balances other than (ii) above	55.15	31.36
	(iv) Other financial assets	75.68	39.50
	(c) Other current assets	1.67	0.20
	Total current assets	4.58	3.15
	TOTAL ASSETS (I + II)	203.92	164.43 463.31
	EQUITY AND LIABILITIES		
I	Equity	1	1
	(a) Equity share capital	995.68	995.68
	(b) Other Equity	(1,342.55)	(1,551.51)
	Total equity	(346.87)	(555.83)
	Liabilities		
II	Non-current liabilities		
	(a) Financial liabilities		
	(i) Borrowings	575.00	327.45
	(ii) Other Financial liabilities	1.45	_
	(b) Provisions	29.79	34.05
	Total non-current liabilities	606.24	361.50
III	Current liabilities		6
	(a) Financial liabilities		
	(i) Trade payables		
	(a)Total outstanding dues of micro and small enterprises	0.94	_
	(b)Total outstanding dues of creditors other than micro and small		****
	enterprises	322.95	436.02
	(ii) Other financial liabilities	60.54	192.31
- 1	(b) Other current liabilities	4.87	14.31
	(c) Provisions	19.85	14.99
	Total current liabilities	409.15	657.63
	Total liabilities ( II + III )	1,015.40	1,019.13
	TOTAL EQUITY AND LIABILITIES (I + II + III)	668.53	463.31

For MEDINOVA DIAGNOSTIC SERVICES LTD

Place: Hyderabad Date: 17.05.2022 HYDERABAD WCAN

SUNIL CHANDRA KONDABALLY MANGING DIRECTOR DIN 01409332

for Shutifundama

4

SECUNDERABAD

# MEDINOVA DIAGNOSTIC SERVICES LIMITED

CIN: L85110TG1993PLC015481

Regd. Office: 7-1-58/A/ FF8, Flat No. 8, Amrutha Business Complex, Ameerpet, Hyderabad - 500 016. STATEMENT OF STANDALONE CASH FLOW FOR THE YEAR ENDED 31ST MARCH, 2022

(Rs. in Lakhs)

	Vassandad	(Rs. in Lakhs
	Year ended	Year ende
Particulars	31.03.2022 Audited	31.03.202 Audite
A Cash flow from operating activities	Addited	Audite
Profit before tax	255.39	229.25
Adjustments for:	200.07	22/020
Depreciation and amortisation expenses	26.01	32.19
Net (gain)/loss on sale of property, plant and equipment	(0.05)	-
Interest income	(3.99)	(7.54
Provision for credit impaired receivables	(0.42)	1.69
Creditors written back	(9.71)	=
Finance costs	41.03	26.88
Operating profit before changes in assets and liabilities	308.26	282.47
Changes in working capital:		
Decrease/(Increase) in trade receivables	27.30	(33.78
Decrease/(Increase) in inventories	(3.50)	(6.74
Decrease/(Increase) in other financial assets	(33.00)	(27.03
Decrease/(Increase) in other tax assets	(8.74)	(-/
	(1.43)	-
Decrease/(Increase) in other current assets		- (40.00
Increase/(Decrease) in trade payables	(102.42)	(48.88
Increase/(Decrease) in provisions and other liabilities	(6.75)	(21.28
Increase/(Decrease) in other financial liabilities	(17.93)	2.91
Cash generated from operations	161.80	147.67
Direct taxes paid/(refund received)	(50.00)	3.15
Net cash from operating activities	111.80	150.82
Cash flows from investing activities		
Acquisition of property, plant and equipment	(16.92)	(18.50
Proceeds from sale of property, plant and equipment	0.79	-
	(170.00)	
Furhter investment in subsidary		7.2/
Interest received	3.99	7.34
Net cash used in investing activities	(182.14)	(11.10
Cash flows from financing activities		
Proceeds of/(Repayment of) loan from holding company	575.00	(70.66
Proceeds of/(Repayment of) loan from Directors	(327.45)	-
Repayment of long-term borrowings		(36.01
Interest paid	(153.41)	(8.36
Net cash from/(used in) financing activities	94.14	(115.03
	22.70	216
Net increase/ (decrease) in cash and cash equivalents (A + B + C)	23.79	24.64
Cash and cash equivalents at the beginning of the year	31.36	6.72
Cash and cash equivalents at end of the year Note:	55.15	31.36
<ul><li>(a) The above Statement of Cash Flow has been prepared under the Standard (Ind AS-7) - Statement of Cash Flows.</li><li>(b) Cash and cash equivalents as per above comprise of the following:</li></ul>	"Indirect Method" as set out in the In	ndian Accountin
	As at	As a
	March 31, 2022	March 31, 202
Cash on hand	1.08	1.77
Balances with banks		
- in current accounts	54.08	29.59
Total cash and cash equivalents	55.15	31.36
Following	r MEDINOVA DIAGNOSTIC SERVI	CES LTD
Place: Hyderabad Date: 17.05.2022	SUNIL CHANDRA KONDAP.  MANGING DIRECTOR	ALLY

NGING DIRECTOR DIN 01409332

# M. ANANDAM & CO.,

### **CHARTERED ACCOUNTANTS**

Independent Auditor's Report on the Quarterly and Year to Date Standalone Financial Results of Medinova Diagnostic Services Limited Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To

The Board of Directors of Medinova Diagnostic Services Limited

Report on the audit of the Standalone Financial Results

### Opinion

We have audited the accompanying standalone quarterly financial results of Medinova Diagnostic Services Limited (the Company) for the quarter ended 31<sup>st</sup> March, 2022 and the year to date results for the period from 1<sup>st</sup> April, 2021 to 31<sup>st</sup> March, 2022, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information for the quarter ended 31<sup>st</sup> March, 2022 as well as the year to date results for the period from 1<sup>st</sup> April, 2021 to 31<sup>st</sup> March, 2022.

### **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Standalone Financial Results* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

SECUNDERABA

### Management's Responsibilities for the Standalone Financial Results

These quarterly financial results as well as the year to date standalone financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

# Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.



As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether
  due to fraud or error, design and perform audit procedures responsive to those risks, and obtain
  audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not
  detecting a material misstatement resulting from fraud is higher than for one resulting from error,
  as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override
  of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit
  procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are
  also responsible for expressing our opinion on whether the company has adequate internal
  financial controls with reference to financial statements in place and the operating effectiveness
  of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the standalone financial results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the standalone financial results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the standalone financial results.



We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

### **Other Matter**

The audited financial results for the quarter and year ended 31<sup>st</sup> March, 2021, included in the financial results, are based on the previously issued results of the Company audited by the predecessor auditors, whose audit reports dated 23<sup>rd</sup> April, 2021 expressed an unmodified opinion on those financial results.

The Financial Results include the results for the quarter ended 31<sup>st</sup> March, 2022 being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For M.Anandam & Co., Chartered Accountants

(Firm Regn.No.000125S)

Madhuri Chimalgi

Partner

Membership No. 235955

UDIN: 22235955AJCMX09762

NDAM

SECUNDERABAL

Place: Hyderabad Date: 17.05.2022

# MEDINOVA DIAGNOSTIC SERVICES LIMITED CIN: L85110TG1993PLC015481

Regd. Office: 7-1-58/A/FF8, Flat No. 8, Amrutha Business Complex, Ameerpet, Hyderabad - 500 016.

### STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH, 2022

(Rs. in Lakhe)

Г		I	Quarter Ended		V	(Rs. in Lakhs)
SI.	Particulars	31.03.2022		21 02 2025	Year	
No.	1 11 11 11 11 11	(Audited)	31.12.2021 (Unaudited)	31.03.2021 (Audited)	31.03.2022 (Audited)	31.03.2021
1	Income:	(Addited)	(Chauditeu)	(Addited)	(Addited)	(Audited)
	(a) Revenue from Operations	269.86	260.49	276.85	1320.19	1274.35
	(b) Other Income	3.42	5.33	7.86	14.64	
	Total Income	273.28	265.82	284.71	1334.83	13.61
2	Expenses	275.26	203,02	204./1	1334.03	1207.90
	(a) Cost of Materials Consumed	40.65	57.48	46.19	254.70	158.40
	(b) Employee Benefits Expense	48.78	50.26	42.53	198.27	172.79
	(c) Testing Fees	24.32	14.07	24.42	173.89	334.68
	(d) Finance Costs	14.18	12.84	11.45	50.94	46.26
	(e) Depreciation	13.59	13.85	18.24	54.65	71.65
	(f) Other Expenses	86.14	75.24	79.39	322.69	307.96
	Total Expenses	227.66	223,74	222,22	1055,14	1091.74
3	Profit before Tax	45.62	42.08	62,49	279.69	196.22
4	Tax Expense					
	(a) Current Tax	5.84	9.27	7.07	60.46	8.51
	(b) Earlier Year's Tax	10.09	1.14	-	11.23	0.43
	(c) Deferred Tax	(7.30)	(7.89)	(3.19)	(30.06)	(3.19)
	Total tax expense	8.63	2.52	3,88	41.63	5.75
5	Profit for the period (3-4)	36.99	39.56	58.61	238.06	190.47
6	Other Comprehensive Income	3000000000				
	Items that will not be reclassified to Profit or Loss (Net of tax)				1	
	Remeasurement of defined benefit plans	2.75	(0.22)	(4.82)	2.09	(4.82)
	Income tax relating to above	(0.53)	`- 1	`- 1	(0.53)	-
7	Total Comprehensive Income for the period (5+6)	39.21	39.34	53.79	239.62	185.65
	Net Profit attributable to:					
	(a) Owners of the Company	34.56	35.63	51.50	226.82	202.21
	(b) Non Controlling Interest	2.43	3.93	7.11	11.24	(11.74)
- 1	Other Comprehensive Income attributable to:					
	(a) Owners of the Company	2.22	(0.22)	(4.82)	1.56	(4.82)
	(b) Non Controlling Interest	-	-	- 1	-	- 1
	Total Comprehensive Income attributable to:					
-	(a) Owners of the Company	36.78	35.41	46.68	228.38	197.39
	(b) Non Controlling Interest	2.43	3.93	7.11	11.24	(11.74)
	Paid-up Equity Share capital (Face Value Rs 10/- per share)	995,68	995.68	995,68	995.68	995,68
9	Earnings per Equity Share (not annualised)					
	a) Basic (Rs.)	0.35	0.36	0.52	2.27	2.03
	b) Diluted (Rs.)	0.35	0.36	0.52	2.27	2.03

#### Notes

- 1. The above Consolidated financial results of Medinova Diagnostic Services Limited ("the company") have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 2. The above consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 17th May, 2022. The Statutory Auditors of the Group have expressed an unmodified audit opinion on these results.
- 3.During the quarter ended 31st March 2022, the Company has acquired balance partnership stake (approx 44.93%) in Medinova Millennium MRI Services LLP.
- 4.The figures for the quarters ended 31 March 2022 and 31 March 2021 are the balancing figures between audited figures in respect of full financial years and the published unaudited year to date figures up to third quarter of the respective financial years.
- 5. The above results include the results of the subsidiary, Medinova Millennium MRI Services LLP
- 6. The Group has one reportable segment (viz. Diagnostic Services) as per the requirements of Ind AS 108 "Operating Segments".
- 7. The Group has prepared consolidated financial results based on Ind AS 110 "Consolidated Financial Statements".
- 8. The Group has considered internal and external sources of information up to the date of approval of these financial results in evaluating the possible affects that may result from the pandemic relating to COVID-19 on the carrying amounts of assets. The Group has applied prudence in arriving at the estimates and assumptions. The Group is confident about the recoverability of the assets.

9. Previous period figures have been regrouped/reclassified, as considered necessary, to conform with the current period presentation, wherever applicable

For MEDINOVA DIAGNOSTIC SERVICES LTD

Place: Hyderabad Date:- 17.05.2022 SUNIL CH MAN

SUNIL CHANDRA KONDAPALLY MANAGING DIRECTOR DIN 01409332

A

SECUNDERABAD SS

# MEDINOVA DIAGNOSTIC SERVICES LIMITED

## CIN: L85110TG1993PLC015481

Regd. Office : 7-1-58/A/ FF8 , Flat No. 8, Amrutha Business Complex, Ameerpet, Hyderabad - 500 016.

Consolidated Balance Sheet as at 31st MAR, 2022

SI			(Rs. in Lakhs)
No.	Particulars	As at	As at
1,0,	Tarticulars	31.03.2022	31.03.2021
	ASSETS	(Audited)	(Audited)
I	Non-current assets		
	(a) Property, plant and equipment	4.044	
	(b) Intangible assets	148.11	187.23
	(c) Financial assets	0.65	-
	(i) Other financial assets	10.00	
	(d) Deferred tax assets, (net)	13.85	18.50
	(e) Non-current tax assets, (net)	58.83	29.31
	Total non-current assets	15.32	30.00
п	Current assets	236,76	265.04
11	(a) Inventories		
	(b) Financial assets	17.68	14.64
	(i) Trade receivables		
	(ii) Cash and cash equivalents	51.77	82.58
	(iii) Bank balances other than (ii) above	55.42	31.69
	(iv) Other financial assets	75.68	39.50
	(c) Other current assets	1.67	0.20
	Total current assets	5.04	3.59
	TOTAL ASSETS (I + II)	207.26	172.20
	101AL ASSETS (1 + II)	444.02	437.24
	EQUITY AND LIABILITIES	1	
I	Equity	1	
	(a) Equity share capital	995.68	995.68
	(b) Other equity	(1,676.56)	(1,715.47)
	Equity attributable to owners of Parent Company	(680.88)	(719.79)
	Non-controlling interest	-	(30.70)
	Total equity	(680.88)	(750.49)
	Liabilities		
II	Non-current liabilities		
	(a) Financial liabilities		
	Borrowings	575.00	327.45
	(b) Provisions	29.79	65.09
	Total non-current liabilities	604.79	392.54
	Current liabilities		
- 1	(a) Financial liabilities		
	(i) Borrowings		
- 1	(ii) Trade payables	63.46	119.69
- 1	(a)Total outstanding dues of and small enterprises		
	(b) Total outstanding dues of creditors other than micro and small	1.17	-
	enterprises		
	(iii) Other financial liabilities	334.05	451.85
	(b) Other current liabilities	62.20	193.80
	(c) Provisions	5.25	14.86
- 1	Total current liabilities	53.98	14.99
- 1	Total liabilities (II + III)	520.11	795.19
	FOTAL EQUITY AND LIABILITIES (I + II + III)	1,124.90	1,187.73
	(1 · II · III)	444.02	437.24

For MEDINONA DIAGNOSTIC SERVICES LTD

Place: Hyderabad Date:- 17.05.2022



SUNII CHANDRA KONDAPALLY MANGING DIRECTOR DIN 01409332

SECUNDERABAD

# MEDINOVA DIAGNOSTIC SERVICES LIMITED CIN: L85110TG1993PLC015481

Regd. Office: 7-1-58/A/FF8, Flat No. 8, Amrutha Business Complex, Ameerpet, Hyderabad - 500 016.

### Statement of Consolidated Cash Flows

	Year ended	(Rs. in Lakt Year end
	31.03.2022	31.03.20
A. Cash flow from operating activities	Audited	Audit
Profit before tax	250 (0	1000
Adjustments for:	279.69	191.4
25 Co. 12		
Depreciation expense	54.65	71.6
Net gain on sale/ retirement of property, plant and equipment Interest income	(0.05)	-
	(3.99)	(12.3
Provision for credit impaired receivables	(0.42)	1.6
Finance costs	50.94	41.3
Advances written-off	(9.72)	-
Operating profit before changes in assets and liabilities	371.11	293.7
Changes in working capital:		
(Increase)/ decrease in inventories	(3.05)	(6.5
(Increase)/ decrease in trade receivables	31.23	(35.3
(Increase)/ decrease in other financial assets	(33.00)	(29.6
(Increase)/ Decrease in Non current tax assets	(7.01)	-
(Increase)/ decrease in other assets	(1.45)	2.5
Increase/(decrease) in trade payables	(106.90)	(44.6
Increase/(decrease) in provisions and other liabilities	2.67	5.5
Increase/(decrease) in other financial liabilities	(28.82)	(19.2
Cash generated from operations	224.78	166.4
Direct taxes paid	(50.00)	2.0
Net cash generated from operating activities (A)	174.78	168.5
. Cash flows from investing activities		
Acquisition of property, plant and equipment and CWIP	(16.92)	(18.5
Proceeds from sale of property, plant and equipment	0.79	-
Purchase of Non Controling Interest	(170.00)	_
Interest received	3.99	12.3
Net cash used in investing activities (B)	(182.14)	(6.13
. Cash flows from financing activities		
Proceeds of/(Repayment of) loan from holding company	575.00	(70.6
Proceeds of/(Repayment of) loan from Directors	(327.45)	(70.00
Repayment of long-term borrowings	(327.13)	(36.0
Proceeds from/ (Repayments of) short-term borrowings, net	(56.23)	(10.70
Interest paid	(160.22)	(19.93
Net cash used in financing activities	31.10	(137.40
Net increase/(decrease) in cash and cash equivalents (A + B + C)	23.73	24.93
Cash and cash equivalents at the beginning of the year	31.69	6.76
Cash and cash equivalents at end of the year	55.42	31.69
Note:	33,42	31.0.
The above Statement of Cash Flows has been prepared under the "Indirect Met Standard (Ind AS-7) - Statement of Cash Flows.	hod" as set out in the Indi	an Accounting
Cash and cash equivalents as per above comprise of the following:		
	As at	As a
	31.12.2021	31.03.202
Cash on hand	1.35	2.10
Balances with banks	1.55	2.10
- in current accounts	39.81	29.59
devouite	34 X I	79 59

For MEDINOVA DIAGNOSTIC SERVICES LTD

Place: Hyderabad Date:- 17.05.2022



SUNIT CHANDRA KONDAPALLY MANGING DIRECTOR DIN 01459332

for Identification of SECUNDERABAD

# M. ANANDAM & CO., CHARTERED ACCOUNTANTS

Independent Auditor's Report on the Quarterly and Year to Date Consolidated Financial Results of Medinova Diagnostic Services Limited Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To

The Board of Directors of Medinova Diagnostic Services Limited

Report on the Audit of Consolidated Financial Results

### Opinion

We have audited the accompanying consolidated annual financial results of Medinova Diagnostic Services Limited (hereinafter referred to as the "Holding Company") and its wholly owned subsidiary (Holding Company and its subsidiary together referred to as "the Group"), for the quarter and year ended 31st March, 2022, attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid consolidated financial results:

- i. include the annual financial results of wholly owned subsidiary, Medinova Millenium MRI Services LLP, India;
- ii. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- iii. give a true and fair view in conformity with the applicable accounting standards, and other accounting principles generally accepted in India, of net profit and other comprehensive income and other financial information of the Group for the year ended 31st March, 2022.

### **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 ("Act"). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

### Board of Directors' Responsibilities for the Consolidated Financial Results

These Consolidated financial results have been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of these consolidated financial results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Group in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors/Partners of the entities included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial results by the Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial results, the respective Board of Directors/Partners of the entities included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors/Partners either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors/Partners of the entities included in the Group are responsible for overseeing the financial reporting process of the Group.

## Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit
  procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are
  also responsible for expressing our opinion on whether the company has adequate internal
  financial controls with reference to financial statements in place and the operating effectiveness
  of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors'/Partners' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information
  of the entities within the Group to express an opinion on the consolidated financial results. We
  are responsible for the direction, supervision and performance of the audit of financial
  information of such entities included in the consolidated financial results of which we are the
  independent auditors.

Materiality is the magnitude of misstatements in the consolidated financial results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the consolidated financial results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the consolidated financial results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

#### Other Matter

The audited financial results for the quarter and year ended 31<sup>st</sup> March, 2021, included in the financial results, are based on the previously issued results of the Company audited by the predecessor auditors, whose audit reports dated 23<sup>rd</sup> April, 2021 expressed an unmodified opinion on those financial results.

The Financial Results include the results for the quarter ended 31st March, 2022 being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For M.Anandam & Co.,

**Chartered Accountants** 

(Firm Regn.No.000125S)

Madhuri Chimalgi

Partner

Membership No. 235955

UDIN: 22235955AJCMUF6169

S MADI

SECUNDERABAT

Place: Hyderabad Date: 17.05.2022